Vista, CA -- AutoGenomics, Inc., a leader in providing automated molecular testing solutions, announced today that it has launched a test for Genotyping Hepatitis C Virus (HCV) on its INFINITI® Plus and INFINITI® High Throughput System (HTS).
The assay is designed to individually detect 6 HCV genotypes (1-6) and 2 subtypes - 1a and 1b in a single test using AutoGenomics’ proprietary multiplexing microarray technology. The test is currently available for Research Use Only and not for use in diagnostic procedures. AutoGenomics intends to apply to the US Food and Drug Administration for premarket approval for the test.
According to World Health Organization estimates, up to 150 million people have chronic HCV infections. In the United States, HCV infection is the most common blood borne infection, with an estimated 3.2 million persons afflicted.1 Targeted species-specific antiviral treatment is successful in 50–90% of persons when initiated, and is able to reduce the development of liver cancer and cirrhosis. 2, 3
“We are making this assay available on our INFINTI® Plus and INFINTI® High Throughput System to reach low, medium and high volume testing sites” said Fareed Kureshy, President and Chief Executive Officer of AutoGenomics.
About AutoGenomics
AutoGenomics Inc., a privately held company based in Vista, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of pharmacogenomics, genetic disorders, infectious disease and cancer. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of precision medicine. www.autogenomics.com.